<DOC>
	<DOCNO>NCT02230553</DOCNO>
	<brief_summary>This open-label phase I/II multi-center study consist two part . Part A study design identify recommended phase 2 dose ( RP2D ) lapatinib combine trametinib patient metastatic KRASm PIK3CA wild-type ( PIK3CAwt ) , CRC , NSCLC , pancreatic cancer . Part B design perform randomize comparison lapatinib-trametinib combination versus standard care therapy patient metastatic KRASm/PIK3CAwt CRC , NSCLC pancreatic cancer .</brief_summary>
	<brief_title>Lapatinib Plus Trametinib KRAS Mutant Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histological cytological proof metastatic CRC , NSCLC pancreatic cancer ; PART B : treat first line therapy metastatic disease . Written documentation know pathogenic KRAS ( exon 2 , 3 4 ) mutation PIK3CA wildtype ( exon 9 20 ) Age â‰¥ 18 year Able willing give write informed consent WHO performance status 0 1 ( part A B ) Any treatment investigational drug within 30 day prior receive first dose investigational treatment . History another primary malignancy Symptomatic untreated leptomeningeal disease Symptomatic brain metastasis History interstitial lung disease pneumonitis Uncontrolled infectious disease know Human Immunodeficiency Virus HIV1 HIV2 type patient Retinal degenerative disease ( hereditary retinal degeneration agerelated macular degeneration ) , history uveitis , retinal vein occlusion , central serous retinopathy , retinal detachment Patients leave ventricular ejection fraction ( LVEF ) &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>